Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy

Recruiting Observational Study
Rectal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Treatment of rectal cancer by standard neoadjuvant chemoradiotherapy protocols leads to a complete response in about 15% of patients, or even a higher fraction if radiotherapy is followed by an Oxaliplatin based chemotherapy as published recently. If patient presents with a (near) complete response at the time of restaging after neoadjuvant treatment, an organ preservation strategy can be an alte…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * \>18 years of age * Informed consent * Diagnosis of rectal cancer, \<12cm from anal verge * Treatment by chemoradiation (short course 5x5 Gy or 28x1.8 Gy with concomitant 5FU) * Re staging with MRI/endoscopy shows (near) complete response (max 2cm tumor scar) * Decision for tr…
Contacts

Andreas Kohler, MD

0041316322111

andreas.kohler@insel.ch

CONTACT

Isabel Huber

0041316322111

isabel.huber@insel.ch

CONTACT